NCT02531854撤回2 期
A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Number of study participants with objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)
研究概览
简要总结
- Open label
- Enrollment in the order of confirmation of eligibility and HPV+ tumor status
- Prospective stratification based on 3 factors, epidermal growth factor receptor (EGFR) mutation status, performance status and first-line induction chemotherapy outcome;
- Randomization (2:1 ratio): (82 patients receiving the combination of pemetrexed plus ADXS11-001 vs. 42 patients receiving pemetrexed alone)
- Treatment Arm: Pemetrexed plus ADXS11-001 immunotherapy
- Control Arm: Pemetrexed only
- Positive control: pemetrexed chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, ≥ 20 years of age
- •Patients with NSCLC
- •Patients whose disease has either responded or not progressed following 4-6 cycles of first-line induction chemotherapy.
- •Patients with documented/confirmed intra-tumor positivity for HPV
- •Patients with no major existing co-morbidities or medical conditions that will preclude administration of therapy, in the opinion of the Investigator
- •Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- •Patients will use contraception during the study
- •Patients with the ability to understand and give written informed consent for participation in this trial
排除标准
- •Women who are pregnant or breast feeding
- •Patients with histologically- or cytologically-confirmed squamous cell-classified NSCLC
- •Patients with disease progression following first-line induction chemotherapy
- •Patients with known active and uncontrolled central nervous system (CNS) or leptomeningeal metastases
- •Patients with an active second primary malignancy or history of another malignancy
- •Patients with inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy, including ≥ Grade 2 neuropathy
- •Patients with inadequate recovery from any previous surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to the start of study treatment
- •Patients with evidence of inadequate organ function as defined in protocol
- •Patients with a known allergy to both of the following antibiotics: ampicillin, trimethoprim-sulfamethoxazole
- •Patients with a known allergy to anti-emetic medications and/or non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen, celecoxib)
- •Patients with a history of severe hypersensitivity reaction to pemetrexed disodium (Alimta® or equivalent), or any of the excipients used in its formulation
- •Patients with a history of an autoimmune disorder requiring systemic treatment within the past 3 months, or a documented history of a clinically severe autoimmune disease or a syndrome that requires systemic steroid or immunosuppressive agents
- •Patients with a known immunodeficiency including patients: with HIV infection, who have undergone previous organ transplantation and require immunosuppressive therapy or long-term immunosuppressive therapy for any other reason
- •Patients with interstitial lung disease or active, non-infectious pneumonitis, active or prior documented inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis)
- •Patients with an active infection requiring systemic therapy, prior to dosing with study drug
- •Patients with any other life-threatening illness, uncontrolled medical condition (e.g., elevated troponin or creatinine; uncontrolled diabetes), significant organ system dysfunction, or clinically significant laboratory abnormality, which in the opinion of the Investigator would either compromise the patient's safety or interfere with evaluation of the study treatment
- •Patients with a psychiatric disorder, substance abuse disorder, or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study-related evaluations
- •Patients with a history of or current evidence of any condition, therapy, or laboratory abnormality that might: confound the results of the trial, interfere with the patient's participation in the trial, or suggest that participation in the trial is not in the best interest of the patient, in the opinion of the treating investigator
研究组 & 干预措施
ADXS11-001 + Pemetrexed
Experimental
干预措施: ADXS11-001 (Drug)
ADXS11-001 + Pemetrexed
Experimental
干预措施: Pemetrexed (Drug)
Pemetrexed Only
Active Comparator
干预措施: Pemetrexed (Drug)
结局指标
主要结局
Number of study participants with objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)
时间窗: 2 years
Number of study participants with progression free survival as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)
时间窗: 2 years
次要结局
- Distribution of overall response rate (ORR) as assessed by RECIST v1.1 and irRECIST(2 years)
- Distribution of duration of response (DR) as assessed by RECIST v1.1 and irRECIST(2 years)
- Distribution of disease stabilization (SD) as assessed by RECIST v1.1 and irRECIST(2 years)
- Distribution of overall survival (OS) as assessed by RECIST v1.1 and irRECIST(2 years)
- Frequency and severity of treatment related adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for study participants on the combination arm(2 years)
研究者
相似试验
已完成
2 期
Adjunctive Therapy to Treat Tibial Shaft FracturesTraumaNCT00533793Kuros Biosurgery AG201
招募中
2 期
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldDuchenne Muscular DystrophyNCT06769633Italfarmaco18
已完成
2 期
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line TherapyNeoplasms, ColorectalColorectal CancerNCT00967616Daiichi Sankyo100
进行中（未招募）
1 期
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AAcute open tibial shaft fracturesMedDRA version: 9.1Level: HLTClassification code 10024956Term: Lower limb fracturesEUCTR2006-005093-40-SKKuros Biosurgery AG200
进行中（未招募）
不适用
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AAcute open tibial shaft fracturesMedDRA version: 9.1Level: HLTClassification code 10024956Term: Lower limb fracturesEUCTR2006-005093-40-CZKuros Biosurgery AG200